


# Protein and Peptide Purification

## Technique Selection Guide



# TECHNICAL INFORMATION

## Ion Exchange Chromatography (IEX)

### High Resolution – High Capacity

IEX separates proteins on the basis of differences in their net surface charge. The separation is based on the reversible interaction between a charged protein and an oppositely charged chromatographic medium. Proteins bind as they are loaded onto a column. Conditions are then altered so that bound substances are eluted differentially. This elution is usually performed by increases in salt concentration or changes in pH. Most commonly, samples are eluted with salt (NaCl), using a gradient elution, as shown in Figure 1. Target proteins are concentrated during binding and collected in a purified, concentrated form.




Fig 1. Typical high resolution IEX separation using linear gradient elution (25–45 column volumes).

The net surface charge of proteins varies according to the surrounding pH. IEX can be repeated at different pH values to separate several proteins that have distinctly different charge properties, as shown in Figure 2.

### Choice of ion exchanger

Begin with a strong exchanger, to allow work over a broad pH range during method development.

### Strong ion exchangers

Q (anion exchange), SP (cation exchange): fully charged over a broad pH range (pH 2 to 12).

### Weak ion exchangers

DEAE and ANX (anion exchange) and CM (cation exchange): fully charged over a narrower pH range (pH 2 to 9 and pH 6 to 10, respectively), but give alternative selectivities for separations.

### Sample volume and capacity

For optimal separations with gradient elution, use approximately one fifth of the total binding capacity. IEX is a binding technique, independent of sample volume.

### Media and Column Selection

Refer to Ion Exchange Selection Guide Code no: 18-1127-31. Use HiTrap™ IEX Selection Kit for media scouting and method optimization.

### Sample Preparation

Samples should be at the same pH and ionic strength as the starting buffer, and free from particulate matter.

### Buffer Preparation

If charge characteristics are unknown try these conditions first:

#### Anion Exchange

Start buffer (A): 20 mM Tris-HCl, pH 7.4  
Elution buffer (B): 20 mM Tris-HCl + 1 M NaCl, pH 7.4  
Gradient: 0–100% elution buffer in 10–20 column volumes

#### Cation Exchange

Start buffer (A): 20 mM Na<sub>2</sub>HPO<sub>4</sub>·x2H<sub>2</sub>O, pH 6.8  
Elution buffer (B): 20 mM Na<sub>2</sub>HPO<sub>4</sub>·x2H<sub>2</sub>O + 1 M NaCl, pH 6.8  
Gradient: 0–100%B in 10–20 column volumes

### Optimization Parameters

1. Select optimal ion exchanger.
2. Select for optimum pH.
3. Select steepest gradient to give acceptable resolution at selected pH.
4. Select highest flow rate that maintains resolution and minimizes separation time.
5. For large scale purifications and capture steps transfer to a step elution to reduce separation times and buffer consumption.

## Hydrophobic Interaction Chromatography (HIC)

### Good Resolution – Good Capacity

HIC separates proteins according to differences in their hydrophobicity. The separation is based on the reversible interaction between a protein and the hydrophobic surface of a chromatographic medium. This interaction is enhanced by high ionic strength buffer which makes HIC an ideal 'next step' for purification of proteins that have been precipitated with ammonium sulphate or eluted in high salt during IEX chromatography. Samples in high ionic strength solution (e.g., 1.5 M NH<sub>4</sub>SO<sub>4</sub>) bind as they are loaded onto a column. Conditions are then altered so that the bound substances are eluted differentially. Elution is usually performed by decreases in salt concentration. Most commonly, samples are eluted with a decreasing gradient of ammonium sulphate, as shown in Figure 3. Target proteins are concentrated during binding and collected in a purified, concentrated form. Other elution procedures are available.




Fig 3. Typical gradient elution.

### Choice of hydrophobic ligand

Select from a range of ligands. Typically the strength of binding of a ligand to a protein increases in the order: ether, isopropyl, butyl, octyl, phenyl.

Highly hydrophobic proteins bind tightly to highly hydrophobic ligands. Screen several hydrophobic media. Begin with a medium of low hydrophobicity if the sample has very hydrophobic components. Select the medium which gives the best resolution and loading capacity at a low salt concentration.

### Sample volume and capacity

For optimal separations during gradient elution, use approximately one fifth of the total binding capacity of the column. HIC is a binding technique, independent of sample volume.

### Media and Column Selection

With HIC the chromatographic medium as well as the hydrophobic ligand affect selectivity. Parameters such as sample solubility, scale of purification, and availability of the correct ligand at the required scale should be considered. Use HiTrap HIC Selection Kit or RESOURCE™ HIC Test Kit for media scouting and method optimization.

### Sample Preparation

Samples should be at the same pH as the starting buffer, in high ionic strength solution, and free from particulate matter.

### Buffer Preparation

Try these conditions first if hydrophobic characteristics are unknown:

Start buffer (A): 50 mM Na<sub>2</sub>HPO<sub>4</sub>·x2H<sub>2</sub>O pH 7.0 + 1.0 M ammonium sulphate  
Elution buffer (B): 50 mM Na<sub>2</sub>HPO<sub>4</sub>·x2H<sub>2</sub>O pH 7.0  
Gradient: 0–100% B in 10–20 column volumes

### Optimization Parameters

1. Select medium from a HiTrap HIC Selection Kit or RESOURCE HIC Test Kit.
2. Select optimal gradient to give acceptable resolution. For unknown samples begin with 0–100%B (0%B = 1 M ammonium sulphate).
3. Select highest flow rate that maintains resolution and minimizes separation time.
4. For large-scale purifications and capture steps, transfer to a step elution.
5. Samples that adsorb strongly to a medium are more easily eluted by changing to a less hydrophobic medium.

## Affinity Chromatography (AC)

### High Resolution – High Capacity

AC separates proteins on the basis of a reversible interaction between a protein (or group of proteins) and a specific ligand attached to a chromatographic matrix. AC can be used whenever a suitable ligand is available.

The target protein(s) is specifically and reversibly bound by a complementary binding substance (ligand). The sample is applied under conditions that favor specific binding. Unbound material is washed away, and the bound target protein is recovered by changing conditions to those favoring desorption. Desorption is performed specifically, using a competitive ligand, or non specifically, by changing the pH, ionic strength, or polarity. Proteins, which are concentrated during binding, are collected in a purified, concentrated form. The key stages in a separation are shown in Figure 4.

AC may also be used to remove specific contaminants. For example, Benzamidine Sepharose™ Fast Flow (high sub) removes serine proteases.




Fig 4. Typical affinity separation.

### Table 1. Examples of affinity applications

	Application
Purification of immunoglobulins	IgG classes, fragments, and subclasses including polyclonal rat IgG, strong affinity to monoclonal mouse IgG, and monoclonal rat IgG
Group Specific Media	nucleotide-requiring enzymes, coagulation factors, DNA binding proteins, α <sub>2</sub> -macroglobulin, lipoprotein lipases, steroid receptors, hormones, interferon, protein synthesis factors
Media for coupling ligands	any -NH <sub>2</sub> containing ligand
Purification of recombinant tagged proteins	Histidine-tagged proteins, GST-tagged proteins

### Sample volume and capacity

Total binding capacity (target protein(s) bound per ml medium) is defined for commercially available affinity media. AC is a binding technique, independent of sample volume.

### Media and Column Selection

Commercial availability of affinity matrices should be considered. Table 1 shows examples of applications for which ready to use affinity media are available. Specific affinity media are prepared by coupling a ligand to a selected gel matrix, following recommended coupling procedures. Further details on media are available in the Affinity Chromatography Selection Guide (Code No. 18-1121-86) and in the Convenient Protein Purification HiTrap Column Guide (Code No. 18-1129-81). Use prepacked HiTrap Affinity columns for method optimization or small-scale purification.

### Sample Preparation

Samples must be free from particulate matter and contaminants that may bind non-specifically to the column.

### Buffer Preparation

Binding, elution, and regeneration buffers are specific to each affinity medium. Follow supplied instructions.

### Optimization Parameters

1. Select correct specificity for target protein.
2. Follow manufacturer's recommendations for binding or elution conditions.
3. Select optimal flow rate to achieve efficient binding.
4. Select optimal flow rate for elution to maximize recovery.
5. Select maximal flow rate for column regeneration to minimize run times.

## Gel Filtration (GF)

### High Resolution (with Superdex™)

Gel filtration separates proteins according to differences in molecular size. The technique should be used when sample volumes have been minimized.

Since buffer composition does not directly affect resolution, buffer conditions can be varied to suit the sample type or the requirements for the next purification, analysis, or storage step. The key stages in a separation are shown in Figure 5.




Fig 5. Typical gel filtration elution.

### Sample volume and capacity

To achieve highest resolution, the sample volume must not exceed 5% of the total column volume. Gel filtration is independent of sample concentration.

### Media and Column Selection

Refer to Gel Filtration Selection Guide (Code: 18-1124-19). In gel filtration, efficient column packing is essential. Use prepacked columns to ensure reproducible results and highest performance.

### Sample Preparation

Samples must be free from particulate matter. Viscous samples should be diluted. During separation, sample buffer is exchanged with buffer in the column.

### Buffer Preparation

Select a buffer in which the purified product should be collected and which is compatible with protein stability and activity. Ionic strength can be up to 150 mM NaCl, to avoid non-specific ionic interactions with the matrix.

When working with a new sample try these conditions first:

Buffer: 0.5 M Na<sub>2</sub>HPO<sub>4</sub>·x2H<sub>2</sub>O, pH 7.0 + 0.15 M NaCl or select the buffer in which the sample should be eluted for the next step

### Optimization Parameters

1. Select a medium that has your target protein close to the middle of its separation range.
2. Select the highest flow rate that maintains resolution and minimizes separation time. Lower flow rates improve resolution of high molecular weight components, while faster flow rates may improve resolution of low molecular weight components.
3. Determine the maximum sample volume that can be loaded without reducing resolution (sample volume should be 0.5–5% of total column volume).
4. To further improve resolution increase column length by connecting two columns in series.

### Group separations

For sample preparation and clarification use Sephadex™ G-25 for desalting, buffer exchange, and removal of lipids and salts from proteins > M<sub>r</sub> 5000.

Gel filtration is also ideal for sample preparation before or between purification steps. Sample volumes of up to 30% of the total column volume are loaded. In a single step, the sample is desalted, exchanged into a new buffer, and low molecular weight materials are removed.

Any sample volume can be processed rapidly and efficiently. The high sample volume load gives a low resolution separation but with minimal sample dilution.

## Reversed Phase Chromatography (RPC)

### High Resolution

RPC separates molecules of differing hydrophobicity based on the reversible interaction between the molecule and the hydrophobic surface of a chromatographic medium. Samples bind as they are loaded onto a column. Conditions are then altered so that the bound substances are eluted differentially. Due to the nature of the reversed phase matrices, the binding is usually very strong and requires the use of organic solvents and other additives (ion pairing agents) for elution. Elution is usually performed by increases in organic solvent concentration, most commonly acetonitrile. Molecules, which are concentrated during the binding process, are collected in a purified, concentrated form. The key stages in a separation are shown in Figure 6.

RPC is often used in the final polishing of oligonucleotides and peptides, and is ideal for analytical separations, such as peptide mapping.

RPC is not recommended for protein purifications if recovery of activity and return to a correct tertiary structure are required, since many proteins are denatured in the presence of organic solvents.




Fig 6. Typical RPC gradient elution.

### Choice of ligand hydrophobicity

Select a polymer or silica-based matrix either C<sub>4</sub>, C<sub>8</sub>, or C<sub>18</sub> n-alkyl hydrocarbon ligands, according to the degree of hydrophobicity required. Highly hydrophobic molecules bind tightly to highly hydrophobic ligands (e.g., C<sub>18</sub>). Screen several RPC media. If the sample has very hydrophobic components (more likely with larger biomolecules), begin with a medium of low hydrophobicity (e.g., C<sub>4</sub> or C<sub>8</sub>). Select the medium that gives the best resolution and loading capacity.

### Sample volume and capacity

RPC is a binding technique, independent of sample volume. Total capacity is strongly dependent upon experimental conditions and the properties of the medium and sample. For optimal conditions during gradient elution, screen for a sample loading that does not reduce resolution.

### Media and Column Selection

In RPC the chromatographic medium as well as the hydrophobic ligand affect selectivity. Screening of different RPC media is recommended. Reversed phase columns should be 'conditioned' by extended equilibration for first time use, after long-term storage, or when changing buffer systems.

### Sample Preparation

Samples should be free from particulate matter and, when possible, dissolved in the start buffer. If sample is insoluble try **1)** 10–30% acetic acid, **2)** 70% formic acid, **3)** 6 M guanidine-HCl, **4)** 100% DMSO (dimethyl sulphoxide), **5)** TFA (trifluoroacetic acid). Note that a very hydrophobic peptide dissolved in DMSO may precipitate or bind irreversibly to an RPC matrix. Test first with aliquots of sample.

### Buffer Preparation

Try these conditions first when sample characteristics are unknown:



Eluent A: 0.1% TFA in 5% acetonitrile  
Eluent B: 0.1% TFA in 80% acetonitrile  
Gradient: 1–100% eluent B in 20 column volumes

### Optimization Parameters



1. Select medium from screening results.
2. Select optimal gradient to give acceptable resolution. For unknown samples begin with 1–100%B.
3. Select highest flow rate that maintains resolution and minimizes separation time.
4. For large-scale purifications, transfer to a step elution.
5. Samples that adsorb strongly to a medium are more easily eluted by changing to a less hydrophobic medium.

# Protein and Peptide Purification



## Sample Preparation






## Capture




## Intermediate Purification





## Polishing



## Peptide Purification




## Micropurification and Analysis




## Purification Strategies

This selection guide offers general guidelines for protein and peptide purification strategies. Selection of the final strategy will always depend upon specific sample characteristics, the condition of the starting material, and the required level of purity.



For every technique used there is a balance between:




Note: In this model capacity refers to amount of target molecule bound per unit volume of medium. Capacity can also refer to sample size, both absolute volume and sample concentration, that can be handled in a single step.

## Guidelines for Purification

- Define objectives  
purity, activity, quantity required for final product  
Examples of approximate purity level requirements:  
Extremely high >99% therapeutic use or in vivo studies  
High 95-99% x-ray crystallography and most physico-chemical characterization methods  
Moderate <95% Antigen for antibody production
  - Develop analytical assays  
fast detection of protein activity and recovery to work efficiently
  - Define sample characteristics to simplify technique selection and optimization
  - Minimize sample handling at every stage  
avoid lengthy procedures that risk losing activity or reducing recovery
  - Minimize the use of additives  
additives may need to be removed in an extra purification step or may interfere with assays
  - Remove damaging contaminants early  
for example, proteases
  - Use a different technique at each step  
take advantage of sample characteristics that can be used for separation (size, charge, hydrophobicity, ligand specificity)
  - Minimize number of chromatographic steps  
extra steps reduce yield and increase time; combine steps logically
- KEEP IT SIMPLE!

## Glossary of Terms

- Sample Characteristics include:** Size, charge, hydrophobicity, affinity for a specific ligand, isoelectric point (pI), pH, and temperature stability.
- Sample Preparation:** Clarification before first chromatographic separation step. May include extraction and/or concentration procedures.
- Capture:** Initial purification of the target molecule from crude or clarified source material. Goal: Rapid concentration, stabilization and isolation.
- Intermediate purification:** Removal of bulk contaminants. Goal: Purification and concentration.
- Polishing:** Removal of trace contaminants (e.g., structural variants). Goal: End product of required high level purity.



## Technical information overleaf

## Further Information

Selection Guides: to select the correct chromatographic medium for a separation step.

Handbooks: to learn more about the details of each chromatographic technique including applications and troubleshooting.

		Code No.
Purification	Protein Purification Handbook	18-1132-29
Affinity	Affinity Chromatography Selection Guide	18-1121-86
	Affinity Chromatography Handbook: Principles and Methods	18-1022-29
	Antibody Purification Handbook	18-1037-46
Gel Filtration	Gel Filtration Selection Guide	18-1124-19
	Gel Filtration Handbook: Principles and Methods	18-1022-18
	Desalting and buffer exchange Selection Guide	18-1128-62
Hydrophobic Interaction & Reversed Phase	Hydrophobic Interaction and Reversed Phase Chromatography: Principles and Methods	11-0012-69
Ion Exchange	Ion Exchange Selection Guide	18-1127-31
	Ion Exchange Chromatography and Chromatofocusing: Principles and Methods	11-0004-21
Applications	Recombinant Protein Purification Handbook: Principles and Methods	18-1105-02
	GST Gene Fusion System Handbook	18-1157-58
Interactive learning	Protein Purifier CD	18-1155-49
	Column Packing the Movie	18-1165-33

## BioProcess™ Media – Made for bioprocessing

Secure Supply	<ul style="list-style-type: none"><li>• Large capacity production integrated with clear ordering and delivery routines-means availability in the right quantity, at the right place, at the right time.</li><li>• Chromatography is our business; making BioProcess Media a safe investment for long-term production.</li></ul>
Validated Manufacture	<ul style="list-style-type: none"><li>• Validated methods for manufacturing &amp; quality control within ISO9001 certified quality system.</li><li>• A certificate of analysis is available for every lot and an MSDS for every product.</li></ul>
Regulatory support	<ul style="list-style-type: none"><li>• Regulatory Support Files detail performance, stability, extractable compounds, and analytical methods. The essential information in these files is an invaluable starting point for process validation, as well as support for clinical and marketing applications submitted to regulatory authorities.</li></ul>
Capture to Polishing	<ul style="list-style-type: none"><li>• BioProcess Media are designed for each chromatographic stage in a process from Capture to Polishing. Take a systematic approach to method development by using BioProcess Media for every stage.</li></ul>
High Productivity	<ul style="list-style-type: none"><li>• High flow rates, capacities, and recoveries available with BioProcess Media contribute to the overall economy of industrial processes.</li></ul>
Sanitization & CIP/Scalability	<ul style="list-style-type: none"><li>• All BioProcess Media can be cleaned and sanitized in place.</li><li>• Packing methods are established for a wide range of scales.</li><li>• Use the same BioProcess Media for development work, pilot studies and routine production for a direct scale up.</li></ul>
Custom Designed Media	<ul style="list-style-type: none"><li>• Provide large-scale users with media designed for specific applications through variations in ligand, coupling chemistry, and base matrix.</li><li>• Custom Designed Media (CDM) are fully tested and quality controlled</li><li>• Some CDM's are made on an exclusive basis for specific customers; others are available on receipt of order.</li></ul>

For contact information for your local office,  
please visit, [www.gelifesciences.com/contact](http://www.gelifesciences.com/contact)

[www.gelifesciences.com/protein-purification](http://www.gelifesciences.com/protein-purification)

GE Healthcare Bio-Sciences AB

Björkgatan 30  
751 84 Uppsala  
Sweden



GE, imagination at work and GE monogram are trademarks of General Electric Company. BioProcess, Drop Design, HiLoad, HiPrep, HiTrap, RESOURCE, Sephadex, Sepharose, SOURCE, and Superdex are trademarks of GE Healthcare companies.

All third party trademarks are the property of their respective owners.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information

© 2007 General Electric Company – All rights reserved.

First published 2002.

GE Healthcare Limited, Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK

GE Healthcare Bio-Sciences Corp., 800 Centennial Avenue, P.O. Box 1327, Piscataway, NJ 08855-1327, USA

GE Healthcare Europe GmbH, Munzinger Strasse 5, D-79111 Freiburg, Germany

GE Healthcare Bio-Sciences KK, Sanken Bldg., 3-25-1, Hyakunincho, Shinjuku-ku, Tokyo, 169-0073 Japan